Ethnobotany and medicinal plants

Botany (B.Sc) · Ecology and applied botany · free study notes for exams, placements and interviews

In short

Ethnobotany is the scientific study of how people — particularly tribal and rural communities — use plants for medicine, food, fibre, dye, ritual and shelter, and how that knowledge is documented, validated and protected. Medicinal botany is its best-developed branch: it identifies the plant, the part used, the active secondary metabolite and the pharmacological action, and sets standards for the crude drug. India has about 8,000 plant species in recorded medicinal use across Ayurveda, Siddha, Unani, Homoeopathy and folk systems, regulated through the Ministry of AYUSH, the Drugs and Cosmetics Act, 1940 and the Biological Diversity Act, 2002. It is examined in B.Sc Botany (Ecology and applied botany, pharmacognosy papers), CSIR-UGC NET Life Sciences and GATE Biotechnology/XL, and is the working knowledge base for jobs at Dabur, Himalaya, Patanjali, Baidyanath, Emami, Zandu, Arya Vaidya Sala Kottakkal, CSIR-NBRI/CIMAP/IIIM, the National Medicinal Plants Board, state forest departments and herbal quality-control laboratories.

Explained

Scope, history and methods of ethnobotany

Definition: the term was coined by John W. Harshberger (1896) for the study of plant use by aboriginal peoples; modern ethnobotany is interdisciplinary — botany, anthropology, pharmacology, chemistry, economics and law.
Indian foundations: *Rigveda* and *Atharvaveda* list healing plants; Charaka Samhita (internal medicine, ~340 drugs), Sushruta Samhita (surgery, ~395 plant drugs), Ashtanga Hridaya (Vagbhata), Bhavaprakasha Nighantu (plant lexicon); Van Rheede's *Hortus Malabaricus* (1678-1693) on Kerala flora; S. K. Jain founded modern Indian ethnobotany and the Society of Ethnobotanists (1980), Lucknow.
Branches: ethnomedicine (health), ethnopharmacology (action of traditional remedies), ethnotaxonomy (folk classification), ethnoecology, archaeo-ethnobotany (palaeoethnobotany — pollen, seeds, phytoliths, carbonised grain), ethnoveterinary medicine.
Field method, in order: (1) select the community/area and obtain prior informed consent (PIC); (2) semi-structured interviews with informants — vaidyas, hakims, medicine men, midwives; (3) record vernacular name, part used, dose, mode of preparation, ailment; (4) collect voucher specimens in triplicate with field notes; (5) prepare herbarium sheets and deposit in a recognised herbarium with an accession number; (6) authenticate botanical identity; (7) cross-check against literature for novelty; (8) phytochemical and pharmacological screening; (9) publish with benefit-sharing agreed.
Quantitative ethnobotany indices: Use Value (UV), Fidelity Level (FL), Informant Consensus Factor (ICF), Relative Frequency of Citation (RFC) — these convert interview data into comparable numbers and are increasingly asked in exams.
Approaches to new drug discovery: *random screening* (low hit rate), *chemotaxonomic* (screen relatives of a known active taxon), and *ethnodirected* (bioprospecting guided by traditional use) — the ethnodirected route has the highest hit rate, which is why ethnobotany has commercial value.

Classification of medicinal plants and crude drugs

By plant part used (organised drugs): root/rhizome (*Rauvolfia*, *Withania*, *Curcuma*), stem/bark (*Cinchona*, *Saraca asoca*, *Terminalia arjuna*), wood (*Santalum*, *Pterocarpus*), leaf (*Adhatoda*, *Digitalis*, *Ocimum*), flower (*Clove* — flower bud, *Saffron* — stigma), fruit (*Terminalia chebula*, *Emblica*, *Piper nigrum*), seed (*Plantago* husk, *Ricinus*), whole plant (*Phyllanthus niruri*, *Bacopa monnieri*).
Unorganised drugs: exudates and extracts with no cellular structure — gums (*gum acacia*), resins (guggul from *Commiphora wightii*), oleo-gum-resins (asafoetida), latex (*Papaver* — opium), volatile oils, fixed oils, aloe juice (*Aloe vera*).
By therapeutic action (pharmacological classification): cardiotonic, antihypertensive, antidiabetic, antimalarial, anticancer, hepatoprotective, adaptogen, anthelmintic, laxative, expectorant, immunomodulator.
By chemical constituent (chemotaxonomic classification): alkaloid-, glycoside-, terpenoid-, tannin-, flavonoid- and volatile-oil-bearing drugs — most useful to a chemist, least useful to a field botanist.
Rasapanchaka — the Ayurvedic framework for a drug: *rasa* (taste), *guna* (property), *virya* (potency), *vipaka* (post-digestive effect), *prabhava* (specific action); the AYUSH formularies describe drugs in these terms, not in terms of molecules.
Classical dosage forms: *churna* (powder), *kwatha/kashaya* (decoction), *arishta/asava* (fermented), *taila* (medicated oil), *ghrita* (medicated ghee), *bhasma* (calcined, usually mineral), *vati/gutika* (tablet), *avaleha* (confection, e.g. Chyawanprash).

Secondary metabolites — the chemistry behind the medicine

Secondary metabolites are not needed for primary growth; they serve defence, attraction and allelopathy, and incidentally act on animal receptors — which is why plants are medicinal.
Alkaloids: nitrogen-containing, basic, bitter, mostly derived from amino acids; precipitated by Dragendorff's, Mayer's and Wagner's reagents. Examples — reserpine (*Rauvolfia serpentina*, antihypertensive), quinine (*Cinchona officinalis*, antimalarial), morphine/codeine (*Papaver somniferum*), atropine (*Atropa belladonna*, *Datura*), vinblastine and vincristine (*Catharanthus roseus*, leukaemia), colchicine (*Colchicum autumnale*), caffeine, nicotine, ephedrine (*Ephedra*), berberine (*Berberis aristata*).
Glycosides: sugar (glycone) + non-sugar aglycone; hydrolysed by acid or enzyme. Types — cardiac glycosides (digoxin, digitoxin from *Digitalis purpurea/lanata*; Keller-Kiliani test), anthraquinone (sennosides from *Cassia angustifolia*, laxative), saponin (diosgenin from *Dioscorea*, glycyrrhizin from *Glycyrrhiza glabra*; froth test), cyanogenic (amygdalin), glucosinolate (sinigrin, mustard), flavonoid (rutin, hesperidin; quercetin is the aglycone of rutin, not itself a glycoside).
Terpenoids: isoprene (C5) units — monoterpenes C10 (menthol, camphor), sesquiterpenes C15 (artemisinin from *Artemisia annua*, antimalarial), diterpenes C20 (taxol/paclitaxel from *Taxus wallichiana*, anticancer; forskolin from *Coleus forskohlii*), triterpenes C30 (asiaticosides, boswellic acids; withanolides are C28 steroidal lactones), tetraterpenes C40 (carotenoids).
Phenolics: tannins (hydrolysable — gallotannin in *Terminalia*; condensed — catechin in *Acacia catechu*; astringent, used in leather and in antidiarrhoeals), coumarins, lignans (podophyllotoxin from *Podophyllum hexandrum*), curcuminoids (*Curcuma longa*).
Others: steroids (diosgenin is the industrial precursor for cortisone and oral contraceptives), essential/volatile oils (steam-distilled — lemongrass, eucalyptus, mentha), resins, and nitrogenous non-alkaloids.
Extraction sequence in the lab: maceration → percolation → Soxhlet (hot continuous) → successive solvents in increasing polarity (petroleum ether → chloroform → ethyl acetate → methanol → water) → concentration → TLC/HPTLC fingerprint → column chromatography → spectral identification (UV, IR, NMR, MS).

Important Indian medicinal plants — plant, part, constituent, use

*Rauvolfia serpentina* (sarpagandha, Apocynaceae) — root — reserpine — hypertension, sedative; a scheduled, trade-restricted species.
*Withania somnifera* (ashwagandha, Solanaceae) — root — withanolides — adaptogen, stress and immunity; India's largest-volume medicinal root crop.
*Bacopa monnieri* (brahmi, Plantaginaceae) — whole plant — bacosides — memory, nootropic.
*Centella asiatica* (mandukaparni) — whole plant — asiaticoside — wound healing, cognition.
*Curcuma longa* (turmeric, Zingiberaceae) — rhizome — curcumin — anti-inflammatory, antiseptic; subject of the landmark 1997 US patent revocation won by CSIR.
*Azadirachta indica* (neem, Meliaceae) — all parts — azadirachtin, nimbin — antibacterial, insecticide, dental care; the EPO neem patent was revoked in 2005.
*Ocimum tenuiflorum* (tulsi, Lamiaceae) — leaf — eugenol — cough, immunity.
*Andrographis paniculata* (kalmegh) — whole plant — andrographolide — hepatoprotective, fever.
*Catharanthus roseus* (sadabahar) — leaf/root — vinblastine, vincristine — Hodgkin's lymphoma, childhood leukaemia.
*Commiphora wightii* (guggul, Burseraceae) — oleo-gum-resin — guggulsterones — arthritis, lipid lowering; critically endangered by destructive tapping.
*Saraca asoca* (ashoka) — bark — tannins, glycosides — gynaecological disorders; bark harvest is the threat.
*Terminalia chebula*, *T. bellirica*, *Emblica officinalis* — fruits — Triphala, the single most-sold Ayurvedic formulation.
*Gymnema sylvestre* (gurmar) — leaf — gymnemic acid — antidiabetic; *Trigonella foenum-graecum* (methi) and *Momordica charantia* (karela) likewise.
*Aloe vera*, *Asparagus racemosus* (shatavari), *Tinospora cordifolia* (giloy), *Phyllanthus niruri* (bhumyamalaki), *Picrorhiza kurroa* (kutki, Himalayan, endangered), *Nardostachys jatamansi*, *Aconitum heterophyllum* (atis), *Swertia chirayita*, *Taxus wallichiana* — the high-altitude ones are the most threatened.
Narcotic/regulated: *Papaver somniferum* (opium — licensed cultivation only, under the NDPS Act, 1985 and the Central Bureau of Narcotics), *Cannabis sativa* (state-licensed), *Ephedra*.

Standardisation, quality control and GACP

Why standardise: a herbal drug's content varies with genotype, soil, season, altitude, harvest stage, drying and storage, so a chemical marker and a limit are needed before it can be a medicine.
Macroscopic/organoleptic: shape, size, colour, odour, taste, fracture, surface.
Microscopy: diagnostic cell characters — stomatal index, palisade ratio, vein-islet number, trichomes, starch grains, calcium oxalate crystals, stone cells, lignified fibres; lycopodium spore method for powder counts.
Physical constants: moisture (loss on drying), total ash, acid-insoluble ash (detects sand/earthy adulteration), water-soluble ash, alcohol- and water-soluble extractive values, swelling index, foaming index, volatile oil content.
Chemical: preliminary phytochemical screening, assay of the marker compound by HPTLC/HPLC/GC-MS, TLC fingerprint profile.
Safety limits: heavy metals (lead, cadmium, mercury, arsenic), pesticide residues, aflatoxins, microbial load — mandatory for AYUSH export under Schedule T.
Authentication tools beyond morphology: DNA barcoding (rbcL, matK, ITS2 for plants), DNA fingerprinting (RAPD, ISSR, SSR) — the accepted answer to powdered-drug substitution.
Indian references and regulators: Ayurvedic Pharmacopoeia of India (API), Siddha, Unani and Homoeopathic Pharmacopoeias; Pharmacopoeia Commission for Indian Medicine & Homoeopathy (PCIM&H), Ghaziabad; the Drugs and Cosmetics Act, 1940 and Rules 1945 — Chapter IVA and Rules 158B, 159-161 cover ASU drug licensing, Schedule T prescribes GMP for ASU manufacture; the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 bars claims of cure for listed diseases; FSSAI regulates nutraceuticals and botanicals as food, not medicine.
Cultivation side: WHO and NMPB Good Agricultural and Collection Practices (GACP) and Good Field Collection Practices; organic certification under NPOP (APEDA); NMPB (under Ministry of AYUSH) runs cultivation subsidy schemes, and the National AYUSH Mission channels state support.

Conservation, law and intellectual property

Threats: 90%+ of raw drug supply in India still comes from wild collection; destructive harvest of roots, bark and whole plants; habitat loss; unorganised trade; no replanting.
Measures: *in situ* — Medicinal Plant Conservation Areas (MPCAs) in forests, sacred groves, biosphere reserves; *ex situ* — botanic gardens, herbal gardens, field gene banks, seed banks, in vitro conservation, cryopreservation, and micropropagation for scarce species; cultivation to shift pressure off the wild; Home Herbal Gardens promoted by NMPB and FRLHT (Bengaluru).
IUCN/CAMP categories are applied through state CAMP workshops; *Commiphora wightii*, *Saussurea costus*, *Nardostachys jatamansi*, *Podophyllum hexandrum*, *Picrorhiza kurroa*, *Aconitum* spp. and *Taxus wallichiana* are among the Indian medicinal plants under trade restriction; *Saussurea costus* is on CITES Appendix I (commercial trade in wild-collected material prohibited), while Appendix II covers *Rauvolfia serpentina*, *Podophyllum hexandrum*, *Taxus wallichiana*, *Nardostachys jatamansi* and others — exports need permits. Lists are revised, so verify the current Appendix and the DGFT/EXIM restricted list before quoting.
Biological Diversity Act, 2002 (amended 2023) with the Biological Diversity Rules, 2024: a three-tier structure — NBA (Chennai), State Biodiversity Boards, Biodiversity Management Committees at local body level, which maintain the People's Biodiversity Register (PBR). Access by foreign entities and transfer of research results need NBA approval; Indian commercial users give prior intimation to the SBB. The 2023 amendment eased obligations for AYUSH practitioners and cultivated medicinal plants — a point examiners now ask.
Access and Benefit Sharing (ABS): Convention on Biological Diversity (1992) and the Nagoya Protocol (2010, India ratified 2012) — prior informed consent, mutually agreed terms, and a share of benefit to the knowledge-holding community. The Kani-Jeevani case (TBGRI, Kerala — *Trichopus zeylanicus*) is India's model benefit-sharing example.
Biopiracy and defence: the turmeric (1997) and neem (2005) patent revocations and the Basmati dispute led CSIR and AYUSH to build the Traditional Knowledge Digital Library (TKDL) — classical formulations transcribed in five languages, mapped to a Traditional Knowledge Resource Classification, and shared with patent offices as prior art. The Protection of Plant Varieties and Farmers' Rights Act, 2001 registers varieties, including farmers' varieties; patents on plants and traditional knowledge are barred by Section 3(j) and 3(p) of the Patents Act, 1970.

Key points

Ethnobotany - study of plant use by indigenous and rural peoples; term coined by Harshberger, 1896.
S. K. Jain - father of modern Indian ethnobotany; *Hortus Malabaricus* (van Rheede) is the earliest detailed Indian regional medicinal flora.
Voucher specimen - the herbarium proof of identity; an ethnobotanical record without one is scientifically worthless.
Ethnodirected bioprospecting - screening guided by traditional use; far higher hit rate than random screening.
Secondary metabolites - defence chemicals that happen to be pharmacologically active; the real basis of herbal medicine.
Alkaloids - basic nitrogenous compounds, tested with Mayer's/Dragendorff's/Wagner's reagents (reserpine, quinine, vincristine).
Glycosides - aglycone + sugar; cardiac (digoxin), anthraquinone (sennoside), saponin (diosgenin), cyanogenic, flavonoid.
Organised vs unorganised drugs - organised have cellular structure (root, bark, leaf); unorganised are exudates (gum, resin, latex, oil).
Rasapanchaka - rasa, guna, virya, vipaka, prabhava: the Ayurvedic description of a drug.
Acid-insoluble ash - the test that exposes sand and earthy adulteration in a crude drug.
Stomatal index, palisade ratio, vein-islet number - quantitative microscopy constants for leaf drug identity.
DNA barcoding (rbcL, matK, ITS2) - authenticates powdered and adulterated drugs where morphology fails.
API and PCIM&H - the Ayurvedic Pharmacopoeia of India and its commission at Ghaziabad set ASU drug standards.
Schedule T, Drugs and Cosmetics Rules, 1945 - GMP requirements for ASU drug manufacture; the 1954 Magic Remedies Act controls advertising.
NMPB and GACP - the Medicinal Plants Board promotes cultivation under Good Agricultural and Collection Practices.
Biological Diversity Act, 2002 (amended 2023) - NBA, SBBs, BMCs and People's Biodiversity Registers govern access and benefit sharing.
TKDL - CSIR-AYUSH prior-art database built after the turmeric and neem patent revocations to stop biopiracy.
Kani-Jeevani (TBGRI) - India's landmark benefit-sharing model under CBD/Nagoya principles.

Formulas and examples

Stomatal index SI = [S / (S + E)] × 100 — S = number of stomata per unit area, E = number of ordinary epidermal cells in the same area; dimensionless.
Palisade ratio = number of palisade cells beneath one epidermal cell (average over four cells) — dimensionless.
Vein-islet number = number of vein islets per mm² of leaf lamina (count in 4 mm², divide by 4).
Loss on drying (% w/w) = [(W₁ − W₂) / W₁] × 100 — W₁ = initial weight (g), W₂ = constant dry weight after 105 °C.
Total ash (% w/w) = (weight of ash / weight of drug taken) × 100; Acid-insoluble ash = (residue after boiling ash with dilute HCl / drug weight) × 100.
Extractive value (% w/w) = (weight of dried extract / weight of drug) × 100.
Yield of marker (% w/w) = (weight of pure isolated compound / weight of dry plant material) × 100.
Use Value UV = ΣU / n — ΣU = total use-reports for a species, n = number of informants.
Fidelity Level FL (%) = (Ip / Iu) × 100 — Ip = informants citing the species for one ailment, Iu = informants citing it for any ailment.
Informant Consensus Factor ICF = (Nur − Nt) / (Nur − 1) — Nur = use-reports in an ailment category, Nt = taxa used; 0 to 1, near 1 = strong agreement.

Example 1 — Stomatal index of a leaf drug. A *Adhatoda vasica* leaf peel field shows 36 stomata and 144 epidermal cells.

SI = 36 / (36 + 144) × 100 = 36/180 × 100 = 20. Compared against the API monograph range, this confirms identity; a value far outside it suggests a substitute leaf.

Example 2 — Ash values and adulteration. 2.00 g of powdered *Senna* leaf gives 0.24 g total ash; boiling that ash with dilute HCl leaves 0.09 g insoluble residue.

Total ash = (0.24 / 2.00) × 100 = 12.0% w/w.
Acid-insoluble ash = (0.09 / 2.00) × 100 = 4.5% w/w.
Pharmacopoeial limits for senna leaf are of the order of 12% total and 2% acid-insoluble ash, so total ash is at the limit while acid-insoluble ash is roughly twice it — the pattern of sand/soil contamination, not of a wrong species. Verify the exact limits in the current API/IP monograph.

Example 3 — Marker yield and raw-material requirement. Dry *Withania somnifera* root assays 0.32% w/w total withanolides. An extract batch must deliver 160 g of withanolides.

Root needed = 160 / 0.0032 = 50,000 g = 50 kg of dry root.
If extraction recovery is only 70%, root needed = 50 / 0.70 = 71.4 kg.
At a farm-gate price of ₹180 per kg of dry root, raw material cost = 71.4 × 180 ≈ ₹12,860 per batch.

Example 4 — Loss on drying and dry-weight conversion. 25.0 g of fresh *Centella asiatica* herb dries to 4.5 g at 105 °C.

Loss on drying = (25.0 − 4.5)/25.0 × 100 = 20.5/25.0 × 100 = 82% w/w; dry-matter content = 18%.
So 1 tonne of fresh herb yields 180 kg of dry drug — the number that decides transport and drying-yard capacity.

Example 5 — Quantitative ethnobotany. In a survey of 40 informants, *Tinospora cordifolia* received 72 use-reports in all, of which 54 informants cited it for fever; 30 informants cited it for any purpose.

UV = 72 / 40 = 1.80 use-reports per informant — a high-value species.
FL for fever = (54 / 30)... this is impossible, because informants citing one ailment cannot exceed those citing the species at all; with Ip = 24 and Iu = 30, FL = (24/30) × 100 = 80%, i.e. strong agreement that its main use is fever. (Always check Ip ≤ Iu before computing FL — examiners plant this inconsistency.)
If the fever category has Nur = 95 use-reports drawn from Nt = 12 taxa, ICF = (95 − 12)/(95 − 1) = 83/94 = 0.883 — close to 1, so healers agree strongly on which plants treat fever.

Classification basis	Grouping used	Strength	Weakness
Morphological (part used)	Root, bark, leaf, fruit, seed, exudate	Easy in the field and for storage	Unrelated actions grouped together
Taxonomic	By family and genus	Shows evolutionary pattern of chemistry	A family may hold both drug and poison
Chemical	Alkaloids, glycosides, terpenoids, phenolics	Links drug to action and assay	Needs laboratory analysis
Pharmacological	By therapeutic action	Directly useful to a prescriber	One plant appears in many groups

Aspect	Traditional / folk medicine	Codified ASU system	Modern (allopathic) drug
Record	Oral, community-held	Classical texts, API/SPI/UPI	Published trials, IP monographs
Dose basis	Healer's judgement	Formulary dose	mg/kg, from PK studies
Regulation	Largely outside licensing	D&C Act Ch. IVA, Schedule T GMP	D&C Act, CDSCO, Schedule Y trials
Evidence	Ethnographic use	Classical + some clinical data	Randomised controlled trials

Where it is used

Herbal and FMCG manufacturing: Dabur, Himalaya Wellness, Patanjali, Emami, Baidyanath, Zandu, Charak, Arya Vaidya Sala Kottakkal and Arya Vaidya Pharmacy — roles in raw-material identification, pharmacognosy QC, HPTLC analysis and vendor audits.
Research institutes: CSIR-NBRI Lucknow, CSIR-CIMAP (aromatic and medicinal crops), CSIR-IIIM Jammu, CSIR-NIScPR (TKDL), ICAR-DMAPR Anand, Central Council for Research in Ayurvedic Sciences (CCRAS), FRLHT/TDU Bengaluru, JNTBGRI Thiruvananthapuram, Botanical Survey of India.
Regulation and government: Ministry of AYUSH, NMPB, PCIM&H Ghaziabad, NBA and State Biodiversity Boards, drug controllers' ASU laboratories, state forest departments managing MPCAs and NTFP trade.
Cultivation and supply chain: contract farming of ashwagandha (Madhya Pradesh, Rajasthan), senna (Tamil Nadu), isabgol (Gujarat), mentha (Uttar Pradesh), *Coleus* (Tamil Nadu), ginger and turmeric (Kerala, Meghalaya); mandis at Neemuch and Delhi's Khari Baoli are the trade hubs.
Essential oil, nutraceutical and cosmetic industry: steam-distilled oils, standardised extracts for export, FSSAI-regulated botanical supplements; GACP and NPOP organic certification work.
Academic and NGO fieldwork: tribal health documentation, People's Biodiversity Registers for BMCs, Home Herbal Garden programmes, and ABS negotiation support.

Interview questions

Q: What exactly is ethnobotany, and who coined the term? A: The scientific study of how human communities, especially indigenous ones, use plants for medicine, food, fibre, ritual and shelter; J. W. Harshberger coined it in 1896.
Q: Why is a voucher specimen compulsory in ethnobotanical work? A: The vernacular name may apply to several species; a deposited herbarium specimen with an accession number is the only permanent, verifiable proof of which plant was actually used.
Q: Why are secondary metabolites, not primary ones, medicinally active? A: They evolved as defence and signalling chemicals, so they bind animal enzymes and receptors; primary metabolites are universal structural and energy molecules with no such specificity.
Q: How do you distinguish an alkaloid from a glycoside in a preliminary test? A: Alkaloids give precipitates with Mayer's, Wagner's or Dragendorff's reagents; glycosides are detected after hydrolysis — Keller-Kiliani for cardiac, Borntrager's for anthraquinone, froth test for saponins.
Q: A powdered root drug is suspected of substitution. How would you confirm its identity? A: Powder microscopy for diagnostic cells plus an HPTLC fingerprint against a reference standard, and DNA barcoding with rbcL/matK/ITS2 if morphology is inconclusive.
Q: What does a high acid-insoluble ash value tell you? A: That the drug carries sand or earthy matter — a collection and washing failure — rather than a different species, which would instead shift the extractive values and microscopy.
Q: Name two Indian biopiracy cases and what came out of them. A: The US turmeric wound-healing patent (revoked 1997) and the EPO neem fungicide patent (revoked 2005); both led CSIR and AYUSH to build the TKDL as documented prior art.
Q: What is the Kani-Jeevani case about? A: TBGRI developed a drug from *Trichopus zeylanicus* using Kani tribal knowledge and shared the licence fee and royalty with a Kani trust — India's model of access and benefit sharing.
Q: Which law governs access to Indian medicinal plants for research or commerce? A: The Biological Diversity Act, 2002, amended in 2023, with the 2024 Rules — NBA approval for foreign access and for transferring results, prior intimation to the State Board for Indian commercial use, and BMCs maintaining People's Biodiversity Registers.
Q: Why is standardisation harder for a herbal drug than for a synthetic one? A: Its content varies with genotype, soil, season, altitude, harvest stage, drying and storage, and the activity often comes from a mixture, so a marker compound plus a fingerprint is used instead of a single pure assay.
Q: Which part of *Commiphora wightii* is used, and why is the plant critically endangered? A: The oleo-gum-resin (guggul) tapped from the stem; unscientific, repeated and deep tapping kills the slow-growing plant, and it is almost entirely wild-collected.
Q: What is GACP and who promotes it in India? A: Good Agricultural and Collection Practices — WHO-derived guidance on site selection, propagation material, harvest stage, drying, storage and documentation for medicinal plants, promoted by the National Medicinal Plants Board under the Ministry of AYUSH.
Q: Give one plant each for malaria, hypertension and leukaemia, with the molecule. A: *Cinchona officinalis* bark — quinine; *Rauvolfia serpentina* root — reserpine; *Catharanthus roseus* — vincristine and vinblastine.

Common mistakes

Writing only the vernacular name in an ethnobotanical record — the binomial, family, part used and voucher number are what carry marks and scientific value.
Confusing alkaloids with glycosides, or quoting the wrong test (Keller-Kiliani is for cardiac glycosides, not alkaloids).
Naming the wrong plant part: *Rauvolfia* is root, *Cinchona* is bark, *Digitalis* is leaf, clove is the flower bud, saffron is the stigma.
Treating total ash and acid-insoluble ash as the same test, and so missing the specific evidence of earthy adulteration.
Assuming "herbal" means safe — *Aconitum*, *Datura*, *Abrus*, *Nerium* and *Cerbera* are lethal, and ASU drugs still need Schedule T GMP and heavy-metal limits.
Crediting the discovery of a drug to the laboratory alone and omitting the community whose knowledge directed the screening — which also means forgetting prior informed consent and benefit sharing.
Quoting IUCN, CITES or statutory lists from an old textbook; they are revised periodically and must be checked against the current notification.